Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis

被引：89

作者：

Zhang, Wei ^{[1
,2
,3
]}

Bai, Ming ^{[1
]}

Yu, Yan ^{[1
]}

Li, Lu ^{[1
]}

Zhao, Lijuan ^{[1
]}

Sun, Shiren ^{[1
]}

Chen, Xiangmei ^{[1
,2
,3
]}

机构：

[1] Fourth Mil Med Univ, Dept Nephrol, Xijing Hosp, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China

[2] Chinese Peoples Liberat Army Gen Hosp, Dept Nephrol, State Key Lab Kidney Dis, 28th Fuxing Rd, Beijing 100853, Peoples R China

[3] Mil Med Postgrad Coll, 28th Fuxing Rd, Beijing 100853, Peoples R China

来源：

CRITICAL CARE | 2019年 / 23卷 / 1期

基金：

中国国家自然科学基金;

关键词：

Anticoagulation; Citrate; Liver failure; Continuous renal replacement therapy; CONTINUOUS VENOVENOUS HEMODIAFILTRATION; CRITICALLY-ILL PATIENTS; ACUTE KIDNEY INJURY; IONIZED CALCIUM; HEMODIALYSIS; HEPARIN; HEMOFILTRATION; HYPOCALCEMIA; METABOLISM; BLOOD;

D O I：

10.1186/s13054-019-2317-9

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

BackgroundRegional citrate anticoagulation (RCA) is a widely used strategy for continuous renal replacement therapy (CRRT). Most of the current guidelines recommend liver failure as one of the contraindications for citrate anticoagulation. However, some studies suggested that the use of citrate for CRRT in liver failure patients did not increase the risk of citrate-related complications. The purpose of this systematic review is to summarize the current evidences on the safety and efficacy of RCA for CRRT in liver failure patients.MethodsWe performed a comprehensive search on PubMed, Embase, and the Cochrane Library databases from the inception to March 1, 2018. Studies enrolled adult (age>18years) patients with various levels of liver dysfunction underwent RCA-CRRT were included in this systematic review.ResultsAfter the study screening, 10 observational studies with 1241 liver dysfunction patients were included in this systematic review. The pooled rate of citrate accumulation and bleeding was 12% [3%, 22%] and 5% [2%, 8%], respectively. Compared with the baseline data, the serum pH, bicarbonate, and base excess (BE), the rate of metabolic alkalosis, the serum ionized calcium (ionCa) and total calcium (totCa) level, and the ratio of total calcium/ionized calcium (totCa/ionCa) significantly increased at the end of observation. However, no significant increase was observed in serum citrate (MD -65.82 [-194.19, 62.55]), lactate (MD 0.49 [-0.27, 1.26]) and total bilirubin concentration (MD 0.79 [-0.70, 2.29]) at the end of CRRT. Compared with non-liver failure patients, the live failure patients showed no significant difference in the pH (MD -0.04 [-0.13, 0.05]), serum lactate level (MD 0.69 [-0.26, 1.64]), and totCa/ionCa ratio (MD 0.03 [-0.12, 0.18]) during CRRT. The median of mean filter lifespan was 55.9h, with a range from 22.7 to 72h.ConclusionsRegional citrate anticoagulation seems to be a safe anticoagulation method in liver failure patients underwent CRRT and could yield a favorable filter lifespan. Closely monitoring the acid base status and electrolyte balance may be more necessary during RCA-CRRT in patients with liver failure.

引用

页数：11

共 48 条

[11] The use of regional citrate anticoagulation for continuous venovenous hemodiafiltration in acute kidney injury [J].

Durao, Marcelino S. ;

Monte, Julio C. M. ;

Batista, Marcelo C. ;

Oliveira, Moacir ;

Iizuka, Ilson J. ;

Santos, Bento F. ;

Pereira, Virgilio G. ;

Cendoroglo, Miguel ;

Santos, Oscar F. P. .

CRITICAL CARE MEDICINE, 2008, 36 (11) :3024-3029

[12] Foreword [J].

Eckardt, Kai-Uwe ;

Kasiske, Bertram L. .

KIDNEY INTERNATIONAL SUPPLEMENTS, 2012, 2 (01) :7-7

[13]

Egger M, 1998, BRIT MED J, V316, P140

[14] Citrate anticoagulation in continuous venovenous hemodiafiltration:: a metabolic challenge [J].

Gabutti, L ;

Marone, C ;

Colucci, G ;

Duchini, F ;

Schönholzer, C .

INTENSIVE CARE MEDICINE, 2002, 28 (10) :1419-1425

[15] Measuring inconsistency in meta-analyses [J].

Higgins, JPT ;

Thompson, SG ;

Deeks, JJ ;

Altman, DG .

BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7414) :557-560

[16] Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation [J].

Khadzhynov, Dmytro ;

Schelter, Christin ;

Lieker, Ina ;

Mika, Alice ;

Staeck, Oliver ;

Neumayer, Hans. -H. ;

Peters, Harm ;

Slowinski, Torsten .

JOURNAL OF CRITICAL CARE, 2014, 29 (02) :265-271

[17] Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction [J].

Klingele, Matthias ;

Stadler, Theresa ;

Fliser, Danilo ;

Speer, Timo ;

Groesdonk, Heinrich V. ;

Raddatz, Alexander .

CRITICAL CARE, 2017, 21

[18] Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients [J].

Kramer, L ;

Bauer, E ;

Joukhadar, C ;

Strobl, W ;

Gendo, A ;

Madl, C ;

Gangl, A .

CRITICAL CARE MEDICINE, 2003, 31 (10) :2450-2455

[19] Regional citrate anticoagulation in continuous venovenous hemodiafiltration [J].

Kutsogiannis, DJ ;

Mayers, I ;

Chin, WDN ;

Gibney, RTN .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (05) :802-811

[20] Sustained low-efficiency dialysis with regional citrate anticoagulation in medical intensive care unit patients with liver failure: A prospective study [J].

Lahmer, Tobias ;

Messer, Marlena ;

Rasch, Sebastian ;

Beitz, Analena ;

Schnappauf, Christopher ;

Schmid, Roland M. ;

Huber, Wolfgang .

JOURNAL OF CRITICAL CARE, 2015, 30 (05) :1096-1100

← 1 2 3 4 5 →